ArticleBMC cancer2025
High frame rate contrast-enhanced ultrasound in hepatocellular carcinoma: biological characteristics and patient outcomes.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- CEUS-based quantitative analysis of washout time in focal liver lesions affects hepatocellular carcinoma diagnosis.Quantitative imaging in medicine and surgery · 2026Article
- Noninvasive prediction of glypican-3 expression and recurrence-free survival in hepatocellular carcinoma using contrast-enhanced ultrasound.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Explainable machine learning-based multiphase contrast-enhanced CT radiomics for noninvasively predicting GPC3 expression in hepatocellular carcinoma: a bicentric study.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo explore the dynamic perfusion process features reflected by preoperative high frame rate contrast-enhanced ultrasound (H-CEUS) in predicting the biological characteristics and recurrence of hepatocellular carcinoma (HCC).
methodsFrom April 2021 to April 2024, 105 HCC patients confirmed by pathology received H-CEUS before radical resection. H-CEUS image features related to differentiation grades, microvascular invasion (MVI), Ki-67 levels and glypican-3 (GPC-3) expression were analyzed. Differences in recurrence-free survival (RFS) according to H-CEUS image features were further compared. The diagnostic performance in predicting HCC recurrence was evaluated.
resultsArborescent vascular morphology on H-CEUS images was an independent risk factor of MVI, high Ki-67 levels and positive GPC-3 expression (P < 0.05). Conversely, fine vascular morphology was associated with the absence of MVI, low Ki-67 levels and negative GPC-3 expression. HCC with poor differentiation and MVI were more frequently classified as LR-M category. Feeding artery showed a significant difference in GPC-3-positive and GPC-3-negative expression (P < 0.05). Over a median follow-up of 17 months, arborescent vascular morphology was significantly correlated to shorter RFS (P < 0.05) and different from fine vascular morphology in RFS after resection. Both LR-M category and feeding artery were not related to RFS. H-CEUS combined with AFP had a good diagnostic performance in predicting HCC recurrence (AUC = 0.813).
conclusionsVascular morphology reflected by H-CEUS was associated with the biological characteristics of HCC. H-CEUS combined with AFP provides a novel preoperative tool to predict HCC recurrence, which is beneficial to guiding the clinical management of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.